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Introduction 
 
Method 
 
 
Figures and Results 
 
Animals:  
Adult male C57BL/6J (n = 48) and BTBR T+ tf/J (n = 48) mice were bred at 
Kenyon College and housed no more than four animals per cage on a 12/12 
hour light/dark cycle with food and water available ad libitum. Twelve animals 
were used for each drug treatment. 
 
Drug Treatments: 
Amphetamine (AMPH) was dissolved in 0.9% NaCl saline, SCH23390 (SCH) 
was dissolved in distilled water, and haloperidol (HAL), which was dissolved in 
tartaric acid, diluted with DI water, and brought to a neutral pH with NaOH. All 
injections were given i.p. at a volume of 3.6µL/g body weight. There were four 
drug treatments, all of which included a pretreatment injection followed by a 
second injection, as described below. 
 
 
 
 
 
 
 
The doses of HAL and SCH23390 (SCH) used did not significantly inhibit 
baseline locomotor activity in pilot studies (Figs. 1,2). 
 
Behavioral Testing: 
Mice were allowed to habituate individually in VersaMax  Animal Activity 
Monitor  Cages (AccuScan Instruments, Columbus, OH, USA) for 30 minutes, 
received pretreatment injections, and were returned to the Activity Monitors for 
another 45 minutes to allow the antagonists to reach maximum effectiveness 
(Cabib). Mice then received injections of saline or amphetamine and locomotor 
activity was monitored  by open field test for the following 60 minutes. 
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Methods 
 
 The BTBR T+ tf/J (BTBR) mouse strain has been demonstrated to have 
good face validity for the cardinal symptoms of autism spectrum disorder due 
to its behavioral phenotypes which include atypical and reduced reciprocal 
social interactions and increased repetitive grooming (McFarlane et al., 2008). 
Ongoing research in the McFarlane lab has observed low tissue levels of 
dopamine in the frontal cortex, hippocampus, and striatum of BTBR. 
Additionally, BTBR were demonstrated to exhibit potentiated locomotor 
hyperactivity in response to a low dose of amphetamine, an indirect dopamine 
agonist, relative to the control mouse strain C57BL/6J (B6). These findings 
suggest that the dopamine system of BTBR differs in some way from that of  
B6. The dopamine pathway is involved in mediating  locomotion and reward 
(Carlson, 2010) and may  therefore contribute to  BTBR’s behavioral 
abnormalities. One possible hypothesis is that the low tissue levels of 
dopamine in BTBR might result in higher sensitivity of dopamine receptors, 
greater receptor density, or both (Kim et al., 2000), which might contribute to 
the potentiation of amphetamine-induced locomotor hyperactivity in BTBR.  
 The present study proposed to evaluate the involvement of the D1 and 
D2 dopamine receptor subtypes in the BTBR amphetamine response by 
administering BTBR and B6 mice with low doses of the D1 antagonist 
SCH23390 and the D2 antagonist haloperidol prior to amphetamine 
administration. In the phenotypically normal B6 mouse strain, this was 
expected to inhibit the increase in locomotor activity  that amphetamine 
normally elicits in rodents (O’Neill and Shaw, 1999). It was hypothesized that 
the degree of locomotor inhibition produced by the antagonists would be more 
pronounced in BTBR than B6, due to greater D1 and D2 dopamine receptor 
sensitivity and/or density. 
I would like to thank Hewlet McFarlane, PhD, for his invaluable guidance and 
support, Becky Gallagher for her assistance with animal breeding and care, the 
Kenyon College Departments of Neuroscience and Psychology, and the 
Summer Scholars Program for funding this project. 
Figure 1. B6 mice administered with 0.06 mg/kg 
HAL (n = 8) did not show significantly diminished 
locomotor activity compared to saline-injected B6 
mice (n = 4) [F(1,59) = 0.594, p = 0.4629].   
Figure 2. B6 mice administered with 0.0075 mg/kg 
SCH (n = 8) did not show significantly diminished 
locomotor activity compared to saline-injected B6 
mice (n = 4) [F(1,59) = 0.591, p = 0.4641].   
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Pretreatment Treatment 
1. Vehicle Saline 
2. Vehicle 2.5 mg/kg AMPH 
3. 0.06 mg/kg HAL 2.5 mg/kg AMPH 
4. 0.0075 mg/kg SCH 2.5 mg/kg AMPH 
Figure 5. B6 and BTBR mice responded differently to 2.5 mg/kg AMPH and high 
doses of  HAL and SCH without pretreatment. To evaluate the effect of pretreatment 
on AMPH response and  to characterize BTBR’s response to higher doses of D1 and D2 
receptor antagonists, C57BL/6J  (n=8 for each treatment) and BTBR T+ tf/J  (n=10 for 
each treatment) mice were administered with either 2.5 mg/kg AMPH, 0.1 mg/kg HAL, or 
0.025 mg/kg SCH and tested for locomotor activity for 60 minutes. The total distance 
traveled was affected by drug treatment [F(2,48) = 28.4765, p < 0.0001], time 
[F(59,2832) = 2.097, p < 0.0001], the interaction between strain and treatment [F(2,48) = 
7.813, p = 0.0012], and the interaction between time, strain and treatment [F(118,2832) = 
7.142, p < 0.0001].   
Conclusion: BTBR mice show an abnormal response to both the dopamine 
agonist amphetamine and the D1 and D2 antagonists haloperidol and 
SCH23390, suggesting  abnormal dopamine system function. The D1 and D2 
antagonists haloperidol and SCH23390 do not reduce amphetamine-induced 
hyperactivity in BTBR mice. Furthermore, BTBR show an abnormally delayed 
response to amphetamine, which is unaffected by the pretreatment regimen 
used in this study.  
 
 The failure of D1 and D2 antagonist administration to reduce 
amphetamine-induced hyperactivity in BTBR mice suggests that their 
abnormal amphetamine response is not directly mediated by an increased 
sensitivity of these two receptor types. Furthermore, BTBR did not 
demonstrate depressed locomotor activity after receiving higher doses of HAL 
or SCH alone, which indicates that these receptors may be less abundant 
and/or sensitive, antithetical to our initial hypothesis. However, our findings 
are suggestive of an abnormal uninvolvement of dopamine receptors in 
BTBR’s amphetamine response. Future research regarding the BTBR mouse 
strain will therefore aim to assess dopamine receptor irregularities, 
characterize the time course of drug responses, and investigate whether the 
dopamine transporter (DAT), another target of amphetamine, mediates 
abnormal amphetamine response.  
Figure 4. BTBR mice exhibit a delayed  response to amphetamine relative to B6 controls. In B6 mice, all 
amphetamine treatments caused significant increases in mean total distance travelled during each 10-minute time 
interval. Conversely, BTBR mice only exhibited maximal amphetamine response  during the last 20 minutes of  the 
locomotor test. Student’s t-test between VEH + Saline  and Pretreatment + AMPH groups, *p < 0.05, §p < 0.01, #p 
< 0.001. 
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C57BL/6J Control 
Figure 3. There was a difference between strains in locomotor response to drug treatment over time. The 
total distance traveled was affected by strain [F(1,88) = 9.552, p = 0.0027], drug treatment [F(3,88) = 7.228, p = 
0.0002], time [F(59,5192) = 10.289, p < 0.0001], the interaction between strain and treatment [F(3,88) = 3.893, p = 
0.0116], and the interaction between time, strain and treatment [F(177,5192) = 2.273, p < 0.0001].  B6 mice 
showed an increase in locomotor activity in response to AMPH that was inhibited by both HAL and SCH, whereas 
there was no significant drug effect for BTBR mice [F(3,44) = 0.523, p = 0.6689]. 
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